Cargando…

The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization

Introduction. Despite a successful percutaneous coronary intervention (PCI), several studies reported that the recurrence of angina after revascularization, even complete, is a particularly frequent occurrence in the first year after PCI. Methods. The aim was to evaluate the efficacy of treatment wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Calcagno, Simone, Infusino, Fabio, Salvi, Nicolò, Taccheri, Temistocle, Colantonio, Riccardo, Bruno, Emanuele, Birtolo, Lucia Ilaria, Severino, Paolo, Lavalle, Carlo, Pucci, Mariateresa, Sardella, Gennaro, Mancone, Massimo, Fedele, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408663/
https://www.ncbi.nlm.nih.gov/pubmed/32635532
http://dx.doi.org/10.3390/jcm9072110
_version_ 1783567883422400512
author Calcagno, Simone
Infusino, Fabio
Salvi, Nicolò
Taccheri, Temistocle
Colantonio, Riccardo
Bruno, Emanuele
Birtolo, Lucia Ilaria
Severino, Paolo
Lavalle, Carlo
Pucci, Mariateresa
Sardella, Gennaro
Mancone, Massimo
Fedele, Francesco
author_facet Calcagno, Simone
Infusino, Fabio
Salvi, Nicolò
Taccheri, Temistocle
Colantonio, Riccardo
Bruno, Emanuele
Birtolo, Lucia Ilaria
Severino, Paolo
Lavalle, Carlo
Pucci, Mariateresa
Sardella, Gennaro
Mancone, Massimo
Fedele, Francesco
author_sort Calcagno, Simone
collection PubMed
description Introduction. Despite a successful percutaneous coronary intervention (PCI), several studies reported that the recurrence of angina after revascularization, even complete, is a particularly frequent occurrence in the first year after PCI. Methods. The aim was to evaluate the efficacy of treatment with ranolazine in addition to conventional anti-ischemic therapy in patients who underwent coronary angiography for persistent/recurrent angina after PCI and residual ischemia only due to small branches not suitable for further revascularization. Forty-nine consecutive patients were included in our registry, adding the ranolazine (375 mg b.i.d) to optimal medical therapy (OMT). The Exercise ECG Test (EET) was performed in all patients before to start the therapy (baseline BL) and at 30 days (T1) after enrollment. Results. The average duration of the exercise was increased after the therapy with ranolazine comparing to baseline (RG 9’1” ± 2’ versus BL 8’10” ± 2’, p = 0.01). Seven (14.3%) patients after receiving ranolazine had not crossed the threshold of six minutes (75 watts) compared to 20 (40.8%) of BL (p = 0.0003). Stress angina appeared more frequently at BL than at 30 days (T1 4.1% versus BL 16.3%, p = 0.04) as well as exercise-induced arrhythmias (BL 30.6% versus T1 14.3%, p = 0.05). Conclusions. The addition of ranolazine to standard anti-ischemic therapy showed a significant improvement in EET results after one month of therapy, including reduced exercise angina, increased exercise tolerance, and reduced exercise arrhythmias.
format Online
Article
Text
id pubmed-7408663
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74086632020-08-13 The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization Calcagno, Simone Infusino, Fabio Salvi, Nicolò Taccheri, Temistocle Colantonio, Riccardo Bruno, Emanuele Birtolo, Lucia Ilaria Severino, Paolo Lavalle, Carlo Pucci, Mariateresa Sardella, Gennaro Mancone, Massimo Fedele, Francesco J Clin Med Article Introduction. Despite a successful percutaneous coronary intervention (PCI), several studies reported that the recurrence of angina after revascularization, even complete, is a particularly frequent occurrence in the first year after PCI. Methods. The aim was to evaluate the efficacy of treatment with ranolazine in addition to conventional anti-ischemic therapy in patients who underwent coronary angiography for persistent/recurrent angina after PCI and residual ischemia only due to small branches not suitable for further revascularization. Forty-nine consecutive patients were included in our registry, adding the ranolazine (375 mg b.i.d) to optimal medical therapy (OMT). The Exercise ECG Test (EET) was performed in all patients before to start the therapy (baseline BL) and at 30 days (T1) after enrollment. Results. The average duration of the exercise was increased after the therapy with ranolazine comparing to baseline (RG 9’1” ± 2’ versus BL 8’10” ± 2’, p = 0.01). Seven (14.3%) patients after receiving ranolazine had not crossed the threshold of six minutes (75 watts) compared to 20 (40.8%) of BL (p = 0.0003). Stress angina appeared more frequently at BL than at 30 days (T1 4.1% versus BL 16.3%, p = 0.04) as well as exercise-induced arrhythmias (BL 30.6% versus T1 14.3%, p = 0.05). Conclusions. The addition of ranolazine to standard anti-ischemic therapy showed a significant improvement in EET results after one month of therapy, including reduced exercise angina, increased exercise tolerance, and reduced exercise arrhythmias. MDPI 2020-07-04 /pmc/articles/PMC7408663/ /pubmed/32635532 http://dx.doi.org/10.3390/jcm9072110 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Calcagno, Simone
Infusino, Fabio
Salvi, Nicolò
Taccheri, Temistocle
Colantonio, Riccardo
Bruno, Emanuele
Birtolo, Lucia Ilaria
Severino, Paolo
Lavalle, Carlo
Pucci, Mariateresa
Sardella, Gennaro
Mancone, Massimo
Fedele, Francesco
The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization
title The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization
title_full The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization
title_fullStr The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization
title_full_unstemmed The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization
title_short The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization
title_sort role of ranolazine for the treatment of residual angina beyond the percutaneous coronary revascularization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408663/
https://www.ncbi.nlm.nih.gov/pubmed/32635532
http://dx.doi.org/10.3390/jcm9072110
work_keys_str_mv AT calcagnosimone theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT infusinofabio theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT salvinicolo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT taccheritemistocle theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT colantonioriccardo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT brunoemanuele theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT birtololuciailaria theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT severinopaolo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT lavallecarlo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT puccimariateresa theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT sardellagennaro theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT manconemassimo theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT fedelefrancesco theroleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT calcagnosimone roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT infusinofabio roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT salvinicolo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT taccheritemistocle roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT colantonioriccardo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT brunoemanuele roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT birtololuciailaria roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT severinopaolo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT lavallecarlo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT puccimariateresa roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT sardellagennaro roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT manconemassimo roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization
AT fedelefrancesco roleofranolazineforthetreatmentofresidualanginabeyondthepercutaneouscoronaryrevascularization